Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INP20 in Peanut-Allergic Patients
2024-518501-17-00Phase 2Authorised
- Sponsor
- InnoUp Farma
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing INP20 with Placebo (2 arms). Primary endpoints: Incidence of adverse events in Part A, Systemic allergic symptoms and relatedness to treatment in Part A and 9 more. Planned start Oct 2024; status: authorised.
02
Drugs
INP20
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2024-518501-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518501-17-00.